DexamethasoneInsulin resistance and off-label use: case report

被引：0

|

作者：

机构：

来源：

Reactions Weekly | 2022年 / 1911卷 / 1期

关键词：

D O I：

10.1007/s40278-022-17470-3

中图分类号：

学科分类号：

摘要：

引用

收藏

页码：173 / 173

相关论文

共 50 条

[41] BevacizumabRetinal breaks and off-label use: case report
Reactions Weekly, 2022, 1924 (1) : 120 - 120
[42] Mirtazapine/pregabalinDelirium and off-label use: case report
Reactions Weekly, 2024, 2029 (1) : 384 - 384
[43] DexamethasoneHyperglycaemia following off-label use: case report
Reactions Weekly, 2022, 1896 (1) : 173 - 173
[44] DexamfetamineHypertension following off-label use: case report
Reactions Weekly, 2021, 1883 (1) : 150 - 150
[45] FavipiravirNephrotoxicity following off-label use: case report
Reactions Weekly, 2022, 1929 (1) : 283 - 283
[46] DexamethasoneAspergillosis secondary to off-label use: case report
Reactions Weekly, 2022, 1935 (1) : 177 - 177
[47] MirtazapineTachyphylaxis following off-label use: case report
Reactions Weekly, 2018, 1703 (1) : 182 - 182
[48] RisdiplamPneumonia following off-label use: case report
Reactions Weekly, 2023, 1950 (1) : 348 - 348
[49] CanagliflozinFanconi syndrome and off-label use: case report
Reactions Weekly, 2020, 1787 (1) : 130 - 130
[50] RivoceranibNeurotoxicity following an off-label use: case report
Reactions Weekly, 2018, 1702 (1) : 232 - 232

← 1 2 3 4 5 →